Benchmark Initiates Coverage On Minimed Group with Buy Rating, Announces Price Target of $20
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Benchmark analyst Bruce Jackson initiates coverage on Minimed Group (NASDAQ:MMED) with a Buy rating and announces Price Target of $20.
Benchmark analyst Bruce Jackson initiates coverage on Minimed Group (NASDAQ:MMED) with a Buy rating and announces Price Target of $20.